Belgian biotech startup Remynd this week said it has licensed its yeast cell-based genotoxicity screening system to drug-discovery firm Galapagos, also located in Belgium, which will use the assay technology in its internal early-stage drug-development programs.
Remynd, a 2002 spin-off from the University of Leuven, hopes that the non-exclusive deal attracts more customers for the assay technology as the company nurtures its own internal drug-discovery programs in Alzheimer’s and Parkinson’s disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.